This session explores evolving network strategies and distribution trends across the pharmaceutical landscape, with a focus on whether manufacturers are shifting toward limited networks or maintaining open distribution. Panelists examine the rationale behind specialty distribution strategies for new therapies, including the influence of REMS programs on channel selection. The discussion compares cost structures across retail, wholesale, and specialty pharmacy models, while also evaluating hybrid and alternative approaches. Attendees gained insight into the complexities of commercial launches, particularly the differences in channel configuration between new product introductions and legacy items. The panel also assessed the impact of limited and self-distribution models, and highlighted solutions that enhance efficiency and access. Finally, experts shared perspectives on future distribution models and the importance of strategic collaboration with channel partners in a rapidly changing industry.